 |
 |
News1 new result for neurturin Ceregene Initiates A New Controlled Phase 2b Trial Of CERE-120 For ... Daily Markets CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 c linical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010). The full article is at: http://www.dailymarkets.com/stock/2010/10/19/ceregene-initiates-a-new-controlled-phase-2b-trial-of-cere-120-for-parkinsons-disease/ __._,_.___ Your email settings: Individual Email|Traditional Change settings via the Web (Yahoo! ID required) Change settings via email: Switch delivery to Daily Digest | Switch to Fully Featured Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe __,_._,___ ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn